Skip to main content
Kenneth Burman, MD, Endocrinology, Washington, DC, MedStar Washington Hospital Center

KennethDaleBurmanMD

Endocrinology Washington, DC

Diabetes, Lipid Metabolism, Thyroid

Professor of Medicine, Georgetown University

Dr. Burman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Burman's full profile

Already have an account?

Education & Training

  • National Capital Consortium
    National Capital ConsortiumResidency, Internal Medicine, 1972 - 1974
  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1970 - 1972
  • University of Missouri-Columbia School of Medicine
    University of Missouri-Columbia School of MedicineClass of 1970

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 1994 - 2024
  • DC State Medical License
    DC State Medical License 1973 - 2022
  • MO State Medical License
    MO State Medical License 1970 - 2023
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2011-2014
  • America's Top Doctors for Cancer Castle Connolly, 2011-2013
  • Top Doctors:Washington DC Area Castle Connolly, 2012
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Other

Press Mentions

  • Experts Debate Benefits and Challenges of New ATA Guidelines & Differentiated Thyroid Cancer
    Experts Debate Benefits and Challenges of New ATA Guidelines & Differentiated Thyroid CancerJanuary 25th, 2016
  • FDA Panel Supports Vascepa Expanded Indication for CVD Reduction
    FDA Panel Supports Vascepa Expanded Indication for CVD ReductionNovember 14th, 2019
  • FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl
    FDA Advisors Recommend CVD Event Reduction Claim for Icosapent EthylNovember 14th, 2019
  • Join now to see all

Professional Memberships

Hospital Affiliations